Next Article in Journal
Neolignans from Nectandra megapotamica (Lauraceae) Display in vitro Cytotoxic Activity and Induce Apoptosis in Leukemia Cells
Next Article in Special Issue
Preliminary LC-MS Based Screening for Inhibitors of Plasmodium falciparum Thioredoxin Reductase (PfTrxR) among a Set of Antimalarials from the Malaria Box
Previous Article in Journal
Tilting Plant Metabolism for Improved Metabolite Biosynthesis and Enhanced Human Benefit
Previous Article in Special Issue
Inhibition of Tapeworm Thioredoxin and Glutathione Pathways by an Oxadiazole N-Oxide Leads to Reduced Mesocestoides vogae Infection Burden in Mice
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 20
Issue 7
10.3390/molecules200712732
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Metal- and Semimetal-Containing Inhibitors of Thioredoxin Reductase as Anticancer Agents

by
Valentina Gandin
1,* and
Aristi P. Fernandes
2,*
1
Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Via Marzolo 5, 35131 Padova, Italy
2
Division of Biochemistry, Department of Medical Biochemistry and Biophysics (MBB), Karolinska Institutet, SE-171 77 Stockholm, Sweden
*
Authors to whom correspondence should be addressed.
Molecules 2015, 20(7), 12732-12756; https://doi.org/10.3390/molecules200712732
Submission received: 1 April 2015 / Revised: 18 June 2015 / Accepted: 8 July 2015 / Published: 14 July 2015
(This article belongs to the Special Issue Thioredoxin and Glutathione Systems)
Browse Figures
Versions Notes

Abstract

:
The mammalian thioredoxin reductases (TrxRs) are a family of selenium-containing pyridine nucleotide disulfide oxidoreductases playing a central role in cellular redox homeostasis and signaling pathways. Recently, these selenoproteins have emerged as promising therapeutic targets for anticancer drug development, often being overexpressed in tumor cells and contributing to drug resistance. Herein, we summarize the current knowledge on metal- and semimetal-containing molecules capable of hampering mammalian TrxRs, with an emphasis on compounds reported in the last decade.

1. Introduction

The maintenance of redox homeostasis is crucial for cell survival and normal cellular function [1]. Cells regulate the redox state by balancing the generation of reactive oxygen species (ROS) with the elimination of ROS by antioxidant molecules and systems. The thioredoxin (Trx) system is central in upholding the thiol redox homeostasis within the cell and is comprised of NADPH and the redox-active thioredoxin reductase (TrxR) and Trx [2]. The thioredoxin system is involved in a wide range of biological functions within the cell, including ROS scavenging, DNA synthesis, cell proliferation, apoptosis and cell signaling [3]. TrxR is a selenoprotein, with a selenocysteine (Sec) incorporated into the active site, and belongs to a class of pyrimidine nucleotide disulfide oxidoreductases. There are three isoforms of TrxR, TrxR1 and TrxR2, which are ubiquitously expressed in cells and located in the cytosol and mitochondria, respectively, and, finally, the testis-specific TrxR3/TGR, which contains an additional glutaredoxin domain. All three isoforms are homodimeric flavoenzymes with their two subunits organized in a head to tail fashion. While the major function of TrxR is to provide electrons to Trx, having a broad substrate specificity, TrxR is also involved in a vast number of additional reactions. With the easily-accessible and highly-reactive Sec-containing active site, TrxR is capable of reducing proteins like TRP14 [4] and small molecular compounds like lipoic acid, dehydroascorbate, cytochrome c and quinones, but also hydroperoxide [5].
Mounting evidence suggests that numerous types of cancer cells have increased levels of ROS [6]. To counteract this, cancer cells often upregulate their antioxidant defense machinery. This, however, leaves a small margin for these cells to cope with additional stress. Cancer cells with elevated ROS production are thus more vulnerable to a compromised antioxidant defense system, which will give rise to a further increase in the levels of ROS, giving rise to oxidative stress and, ultimately, cell death. Therefore, manipulating ROS levels by redox modulation is an encouraging way to selectively kill cancer cells without causing significant toxicity to normal cells [7,8]. Moreover, the expression levels of the cytosolic isoform Trx1 and TrxR1 are increased in several human carcinomas [9] and linked to tumor aggressiveness, chemo-resistance and to resistance to apoptosis [10,11,12,13,14]. In view of the above-mentioned findings, TrxR has been suggested as a promising target in cancer treatment (Figure 1A). Indeed, there are a large number of TrxR inhibitors that have been developed and identified over the years, and several of these compounds exhibit cytotoxic properties in tumor cells [15]. The TrxR inhibitors’ mode of action on TrxR inhibition is diverse and includes both competitive, noncompetitive, irreversible and mechanism-based inhibition (for more detailed examples on this matter, see [16]). The inhibitors may, for instance, act by binding to the NADPH binding site or the cysteine (Cys) or selenocysteine (Sec) residues of the two redox active sites of the enzyme (Figure 1B). Inhibitors may also bind to other sites, like the monomer to monomer interface of the homodimer. Most irreversible inhibitors of TrxR apparently act via a reaction with one or more redox-active residues (Cys and Sec), as they do not affect the enzyme in the absence of NADPH. One group of TrxR inhibitors is the metal-containing compounds, which are capable of transferring the metal ion to the catalytic Sec residue. With a highly-nucleophilic Sec residue (pKa = 5.2) positioned on its flexible and very easily-accessible carboxy-terminal position, TrxR can be selectively and irreversibly inactivated by reaction with electrophilic compounds. Conversely, such targeting of the active site of TrxR gives rise to the inhibition of the Trx system.
In recent years, a large quantity of metal-containing molecules have been found to exert their biological activities via DNA-independent mechanisms, involving enzyme inhibition pathway(s), and recent studies pointed out that TrxR constitutes an effective biomolecular target for a variety of metal-based drugs. Actually, the presence of the Sec residue in TrxR, endowed with a much higher reactivity to bind the “soft” metal ions than thiols, makes TrxR a feasible target for various metallodrugs. Herein, we provide a brief overview of metal- and semimetal-containing TrxR inhibitors, with special attention on those reported in the last decade.
Molecules 20 12732 g001 550
Figure 1. (A) Schematic summary of the various effects caused by TrxR inhibitors; (B) X-ray structure of mammalian TrxR (PDB; http://www.rcsb.org/pdb/).
Figure 1. (A) Schematic summary of the various effects caused by TrxR inhibitors; (B) X-ray structure of mammalian TrxR (PDB; http://www.rcsb.org/pdb/).
Molecules 20 12732 g001

2. Gold-Based Inhibitors

Gold-containing drugs, which have been used in medicine for ages, have been validated as potent and irreversible in vitro TrxR inhibitors in the nanomolar range. The first gold-containing compounds that were proven to affect TrxR were the gold(I)-thiolate drugs, utilized in the treatment of rheumatoid arthritis. The interaction of gold(I) with TrxR was first addressed by Hill and collaborators, which were the first authors reporting the effect of aurothioglucose (1, Figure 2) on rat TrxR [17]. Concomitantly, Gromer et al. studied aurothioglucose and auranofin (2, Figure 2) as inhibitors of purified human TrxR1 [18]. Rigobello et al. reported that auranofin is also proficient in inhibiting mitochondrial rat TrxR2, thus leading to stimulation of permeability transition and mitochondrial swelling in isolated purified mitochondria [19,20], as well as oxidative stress, cytochrome c release and cell death through apoptosis in human cancer cells [21,22].
Although gold(I) derivatives have been shown to exert both glutathione peroxidase (GPx) and TrxR inhibitory action by forming a three-coordinate intermediate gold(I)–selenolate complex [23,24,25,26], TrxR is far more susceptible toward inhibition by gold(I) compounds than the selenoenzyme GPx. Auranofin hampers TrxR activity in near stoichiometric concentrations, with a formal Ki of 4 nM [18], whereas GPx is inhibited in the micromolar range, thus requiring a 1000-fold higher concentration for its inhibition. The difference in enzyme inhibition has been related to the position of the Sec residue in these selenoenzymes, which is fairly more accessible in TrxR than in GPx. Hence, auranofin acts as a potent and more selective inhibitor of TrxR over GPx. In addition, gold complexes derived from the lead compound auranofin have demonstrated a considerable selectivity for the inhibition of TrxR over glutathione reductase (GR) or other structurally-similar enzymes. This selectivity is commonly attributed to the higher affinity of the gold center to selenium compared to sulfur, rendering the nucleophilic selenolate of reduced TrxR the prime target site of modification by this metal. This has also been experimentally confirmed by using mutant forms of TrxR, bearing a Cys residue in the place of Sec. These mutants were significantly less sensitive to inhibition by metallodrugs than the native proteins [27]. This enzyme selectivity exerted by auranofin against TrxR ideally fits with one of the most important paradigms in anticancer drug design, the activity towards a single macromolecular target that is overexpressed in cancer cells, thus making this drug a feasible candidate for cancer therapy. However, despite that fact, auranofin has only recently entered clinical trials as an anticancer agent for the treatment of recurrent epithelial ovarian, primary peritoneal or fallopian tube cancer [28]. The reason(s) that curtailed the use of auranofin in the treatment of cancer could be found in the severe clinical toxicity shown by this gold-based drug in arthritic patients, including proteinuria, diarrhea and bone marrow suppression [29]. In addition, the pharmacokinetic profile of auranofin appears to be significantly affected by the lability of the metal–thioglucose bond, which determines a weak stability of the complex into the blood and a rapid metabolization of the drug due to its conjugation to serum proteins, especially albumin [30,31]. On these bases, a more rational development of novel “auranofin-like” gold(I) complexes, encompassing the optimization of both phosphine and thiol ligands, has been pursued. Many highly promising novel gold(I) species have been reported, shedding also more light on the issue of structure-activity relationships (SAR’s). Keeping in mind that the lability of the thiolate group contributes to defining the biodistribution and kinetic properties of gold(I) complexes, we recently developed a series of linear, P–Au–X “auranofin-like” gold(I) Complexes 3–9 (Figure 2), maintaining the [Au(PEt3)]+ moiety and replacing the unstable thioglucose anion with other thiolates, as well as halogens (X) [32]. Ligands possessing a different binding strength to the gold center were employed, with the aim of investigating an eventual SAR effect based on the different stability of the Au–(X) bond. Although being more efficient against the cytosolic isoform than for the mitochondrial TrxR2, all of the tested compounds were able to selectively inhibit TrxR, with IC50 values in the low or sub-nanomolar range (IC50 values in the 0.31–1.8 nM range towards TrxR1 and in the 0.7–10 nM range towards TrxR2). Their efficacy in hampering TrxR in human ovarian cancer cells was correlated with the nature of the X ligand and its affinity to the Au(I) center. Actually, compounds with halogens, which are hard bases that can easily dissociate from the metal center and result in the formation of charged gold(I) species, showed difficulty in crossing the cellular membranes and inhibiting cancer cell TrxR. Conversely, the most potent compounds were those containing soft bases as X ligands, namely thiocyanate, cyanate, dithiocarbamate and xanthate ligands, showing a high ability to reach the intracellular compartment and to inhibit the selenoenzyme. On the other hand, these differences in cellular accumulation and enzyme hampering did not confer an extensive difference in cancer cell growth inhibition potential, as the IC50 values calculated for all derivatives were strictly comparable and in the low or sub-micromolar range. Only in the case of the cationic [Au(tu)(PEt3)][Cl] Complex 9, a scarce cellular uptake and a significantly lower enzyme inhibition potency were greatly consistent with a cytotoxicity up to seven-times inferior compared to auranofin. This study pointed out that the potency of phosphine containing “auranofin-like” gold(I) complexes, of the type P–Au–X, should be tuned by modulating X ligand affinity to the Au(I) center, thus obtaining complexes that are endowed with different abilities to cross the cell membrane and reach the intracellular target.
Molecules 20 12732 g002 550
Figure 2. Structures of phosphine gold(I)-based inhibitors.
Figure 2. Structures of phosphine gold(I)-based inhibitors.
Molecules 20 12732 g002
Following the perspective of replacing the thiol-carbohydrate moiety with S-donor ligands displaying pharmacological activity themselves, Ott and coworkers developed a gold(I) phosphine complex containing a naphthalimide ligand, N-(N′,N′-dimethylaminoethyl)-4-mercapto-1,8-napthalimide (10, Figure 2) [33]. The choice of this ligand was driven by the presence of a heterocyclic naphthalimide core and a side chain containing a protonable nitrogen, which enable DNA intercalation and binding to the DNA phosphate backbone, respectively. Although the luminescent Compound 10 was a slightly weaker inhibitor of TrxR when compared with the parental compound Et3PAuCl (in vitro IC50 of 0.27 and 0.14 μM for 10 and Et3PAuCl, respectively), it was capable of accumulating strongly and more efficiently in cancer cell nuclei in comparison to Et3PAuCl, hence allowing a more potent cytotoxic effect against breast and colon cancer cells. Nevertheless, despite the fact that a 26-fold increase in cancer cell accumulation was achieved with 10 in MCF-7 cells, the cytotoxicity profile of 10 exceeded that of Et3PAuCl by only 2.5 times.
In an attempt to improve the solubility, stability and bioavailability of the previously reported chlorinated phosphole-containing gold(I) Complex 11 (Figure 2), Viry et al. reported on a phosphole-containing gold(I) complex bridging a diverse thiosugar, 1-thio-β-d-glucopyranose 2,3,4,6-tetraacetato-S({1-phenyl-2,5-di(2-pyridyl)phosphole gold) (12, Figure 2) [34]. Complex 12 was capable of selectively inhibiting TrxR in MCF-7 cells (IC50 value of 1.9 μM), showing a cytotoxicity potency in the low-micromolar range. Subsequently, the authors proved that 12 was effective at inhibiting a malignant glioma growth in vivo, in a C6 glioma rat model [35]. Interestingly, derivative 12 was significantly more effective than the corresponding chlorinated compound, 11. On the other hand, besides being both TrxR inhibitors, the gold(I) chloro- and thiosugar-substituted phospholes have been shown to also interact in vitro with DNA, albeit the latter more weakly. Hence, the mechanism accounting for their cancer cell killing effect may rely on both TrxR inhibition and DNA interaction. Serebryanskaya and co-workers subsequently reported the evaluation of a series of tetrazole-containing triphenylphosphane and triphenylfurane gold(I) Complexes 13–17 (Figure 2) [36]. The introduction of a 1(R)-5-thiotetrazolate ligand led to the obtainment of effective and selective inhibitors of TrxR, with in vitro enzyme IC50 values in the low nanomolar range. The cytotoxicity of all derivatives were in the low micromolar level, with IC50 values against breast and colon cancer cells ranging from 8.5–13.3 μM.
Based on the fact that one of the main limitation of gold(I) compounds is their poor water solubility, which can hinder in vivo bioavailability, Dyson and co-workers synthesized a series of linear P–Au–S gold(I) complexes containing hydrophilic water-soluble phosphine ligands, namely 1,3,5-triaza-7-phosphaadamantane (PTA), 3,7-diacetyl-1,3,7-triaza-5-phosphabicyclo[3.3.1]nonane (DAPTA) and sodium triphenylphosphine trisulfonate (TPPTS) [37]. All Complexes 18–24 (Figure 2) elicited in vitro TrxR inhibitory effects (IC50) in the low nanomolar range, being more efficient against the cytosolic isoform (0.62–1.92 nM range) than for the mitochondrial TrxR2 (4.12–6.95 nM range). Notably, no large variations in the ability to inhibit TrxR were detected among all seven gold compounds, which all elicited IC50 values against TrxR1 very similar to those obtained with auranofin. All derivatives showed a cytotoxic activity in both cisplatin-sensitive and -resistant ovarian cancer cells, with IC50 values in the 4–16 µM range. However, their antiproliferative activity was inferior to that produced by auranofin, thus suggesting that the coordination of highly hydrophilic phosphine ligands to the Au(I) metal center does not confer a higher cytotoxic profile, at least in vitro. In addition, Ortego and collaborators developed a series of thiolate-aminophosphine gold(I) Complexes 25–31 (Figure 2) [38]. Their results clearly suggested that the characteristics of the aminophosphine group coordinated to the gold(I) atom strongly affects their ability to inhibit TrxR. Even if all complexes exhibited a high antiproliferative potential in the low micromolar range (0.34–18.96 μM), no clear relationships between cytotoxic activity and the TrxR inhibition extent were found. Actually, the most cytotoxic Complex 31 (IC50 of 0.34 μM against HeLa cells) inhibited the TrxR enzymatic activity to a lesser extent (38%) than Complexes 25 (77%) and 27 (84%), the latter eliciting IC50 values of 1.7 and 3.29 μM against HeLa cells, respectively. On the contrary, the introduction of a thiosemicarbazone ligand in place of the thiolate led to the preparation of gold(I) Complexes 32–35 endowed with a reduced ability to target TrxR, with in vitro enzyme IC50 values in the micromolar range (Figure 2) [39].
Later, a substitution of the thiolate moiety with P, N, O and C donor ligands was attempted by many authors, with the aim of obtaining compounds showing a suitable stability and solubility under physiological conditions. Galassi and co-workers developed a series of pyrazole and imidazole phosphane gold(I) Compounds 36–43 (Figure 2) containing either hydrophilic (PTA) or lipophilic (PPh3, triphenylphosphane) phosphane ligands [40]. These gold(I)–phosphane complexes inhibited both isolated cytosolic (IC50 values in the 3.5–86.54 nM range) and mitochondrial (IC50 values in the 33.57–258.30 nM range) TrxRs at concentrations that scarcely affected the GPx and GR. Again, TrxR1 was more susceptible to gold(I) derivatives than the corresponding mitochondria isoform. Interestingly, when compared with the PTA derivatives, the hydrophobic PPh3 analogs appeared to be much more cytotoxic against cancer cells, with mean IC50 values in the submicromolar range. Among the PPh3 series, by increasing the deactivation potency of the substituents on the pyrazole ring, an increase in the antiproliferative activity was achieved (37 > 36 > 40). This effect was less marked in terms of TrxR inhibition, the TrxR hampering ability of derivative 36 being slightly higher than that elicited by 37. Based on evidence that bis-chelated gold(I) phosphine complexes have shown great potential as anticancer agents, Rackham and collaborators studied the TrxR inhibitory activity and the anticancer potential of a bis-chelated Au(I) bidentate phosphine complex of the novel water-soluble ligand 1,3-bis(di-2-pyridylphosphino)propane (d2pypp) (44, Figure 2) [41]. They showed that Compound 44 inhibited the activities of both isolated Trx and TrxR at a low micromolar level and that this effect was accounting for its preferential cytotoxicity against cancer cells, Trx and TrxR inhibition being more marked in breast cancer cells than in mammary epithelial cells. Subsequently, Wetzel and co-workers developed a series of linear and tetrahedral bis-chelated gold(I) complexes of the type [(diphos)(AuCl)2] and [(diphos)2Au]X, with imidazolyl- and thiazolyl-based water-soluble diphos-type ligands [42]. Although all [(diphos)2Au]X derivatives were able to selectivity target TrxR in in vitro screenings (IC50 in the 0.12–1.22 µM range), the bis-chelated gold(I)-complex possessing an intermediate lipophilicity (logD = 1.41) showed the highest in vitro antitumor activity, eliciting IC50 values in the sub-micromolar range against ovarian adenocarcinoma cells sensitive and resistant to cisplatin. Later, Wang and collaborators described a novel soluble bis-chelated gold(I)−diphosphine Compound 45 (Figure 2) with a strong and selective anticancer activity, with IC50 values in the low micromolar range against a broad spectrum of cancer cell lines [43]. Remarkably, derivative 45 was able to significantly reduce tumor growth in several tumor xenografts models, without inducing severe adverse effects. Studies on its mechanism of action confirmed that it specifically inhibits isolated TrxR at nanomolar levels, by binding to the C-terminal redox site, without targeting other well-known selenol- and thiol-containing biomolecules.
With the aim of gaining more insight into the biological effects obtained by modulating the coordination environment and the physicochemical properties of gold(I) complexes, Santini et al. prepared and characterized three water-soluble cationic gold(I) homoleptic phosphine complexes of the type [Au(L)4]+, where L is thp = tris(hydroxymethyl)phosphine, PTA, or thpp = tris(hydroxypropyl)phosphine [44]. Among the tested cationic compounds, the most hydrophilic thp derivative 46 showed the highest cytotoxic activity (average IC50 value of 19.68 µM) and was able to induce a 50% decrease of TrxR activity in vitro at 4.2 nM. Likewise, Lupidi and co-workers developed a mixed phosphine gold(I) Complex 47 (Figure 2) containing tris(tert-butyl) phosphine (tBu3P) and bis(diphenylphosphino)ethene (dppet) ligands [45]. The compound was endowed with a high in vitro antitumor efficacy against human colon cancer cells, and its ability to inhibit TrxR in human colon cancer cells at low micromolar levels in a dose-dependent manner was also established. Later, Meyer and co-workers focused their attention on a series of six alkynyl phosphine gold(I) Complexes 48–53 (Figure 2). All derivatives demonstrated a significant antiproliferative activity, with IC50 in the low and sub-micromolar range (0.8 and 12.0 µM), and were able, although to different extents, to selectivity inhibit TrxR in vitro at nanomolar concentrations (IC50 values in the 0.045–1.4 µM range) [46]. However, as outlined for other derivatives, the authors evidenced that the differences in activity against TrxR did not always translate to a substantially higher cytotoxic activity.
Molecules 20 12732 g003 550
Figure 3. Structures of N-heterocyclic carbene (NHC) gold(I)-based inhibitors.
Figure 3. Structures of N-heterocyclic carbene (NHC) gold(I)-based inhibitors.
Molecules 20 12732 g003
Motivated by the great potential of N-heterocyclic carbene (NHC) metal complexes in drug design and owing to NHC ligands’ similar donor properties to phosphines, very recently, several researchers have focused their attention towards the development Au(I) NHC as TrxR inhibitors. This class of derivatives exhibits very encouraging results, being able to efficiently and selectively inhibit TrxR. Among them, the linear cationic Au(I) NHC complexes, developed by the Berners-Price group, showed very interesting biological properties, including the selective inhibition of TrxR, a preferential cytotoxicity against tumor cells over normal ones and the triggering of apoptotic cell death [47]. Interestingly, the degree of selectivity against tumor cells correlated well with their log P values, with the compound possessing intermediate lipophilicity showing the most optimal selectivity and cytotoxic potency compared with the other two compounds. Following the success obtained by Berners-Price, Ott and collaborators developed a series of gold(I) complexes with benzimidazole-derived NHC ligands 54–57 (Figure 3) [48]. These mono-NHC gold(I) complexes were proven to selectively inhibit TrxR at low- and sub-micromolar concentrations (IC50 values in the 0.009–4.0 μM), even though to a lesser extent compared with gold(I) phosphine derivatives, i.e., auranofin, triethylphosphine gold chloride (TEPAuCl) and TPPAuCl. On the other hand, these mono-NHC gold(I) complexes were shown to induce an antiproliferative effect at micromolar doses against different cancer cell lines, with IC50 values in the 4.6–60.7 μM range. Remarkably, they retained an adequate stability against thiols under biological conditions, a property that is highly desirable in the drug development of novel metal-based drugs. The same authors subsequently replaced the chloride ligands of the most cytotoxic derivative 55, introducing ligands endowed with a higher coordinative stability, namely an additional NHC or a PPh3 ligand [49]. The coordination with these neutral ligands led to the formation of cationic species (58 and 59, Figure 3), retaining the ability to preferentially inhibit TrxR over structurally-related enzymes. The neutral chlorido derivative exhibited, beside a stronger and selective TrxR inhibition (in vitro IC50 of 0.36 µM) compared to the cationic Au(I) NHCs, an intensive binding to albumin, similar to that of auranofin. Conversely, the cationic complex 58, with two NHC ligands, elicited a weaker inhibition of TrxR (in vitro IC50 of 4.89 µM), but retained a very scarce ability to bind albumin. Finally, the PPh3 derivative 59 led to a stronger inhibition of TrxR (in vitro IC50 of 0.66 µM) and an elevated protein binding ability. Accordingly, the mitochondrial inactivation (determined as the inhibition of mitochondrial respiration and mitochondrial membrane depolarization) against cancer cells was dependent on the type of coordinated ligand and the charge of the complexes. Concerning cancer cell selectivity, only Compound 58 showed a certain preference for tumor cells over non-transformed ones. This study thereby suggests that the introduction of ligands endowed with a different coordinative stability and/or the formal charge of the complexes could produce significant changes in the enzyme interaction profile of gold(I) NHC complexes, as well as on their putative pharmacokinetic behavior. In this respect, some of these authors later reported that the introduction of different alkyl residues at the phosphorus atom led to major changes in the biological activity and cellular bioavailability [50]. In particular, the bioactivities of Compounds 60–63 (Figure 3) were correlated with both complex reactivity and the extent of cellular accumulation, the latter being dependent to the lipophilicity of the substituents. Concerning TrxR inhibition, all derivatives were able to hamper 50% of the TrxR activity at sub-micromolar concentrations (0.03–0.66 µM), and by decreasing the size of the residues at the phosphorus atom, a stronger inhibition of TrxR was achieved. On the contrary, the most cytotoxic compound of the series was 60, bearing the triphenylphosphane moiety, with IC50 values in the sub-micromolar range. This discrepancy was tentatively explained by the authors taking into consideration that, besides TrxR, PARP-1 was identified as an additional molecular target accounting for the bioactivity of these complexes. Subsequently, the same authors also demonstrated that the coordination of a naphthalimide moiety, which they had previously shown to confer DNA binding and nuclei accumulation abilities to the gold(I) complexes [33], in the imidazole-based NHC fragments of a chloride gold(I) derivative, led to the obtainment of metallodrugs with TrxR inhibitory activity in the submicromolar range and endowed with antiproliferative potential [51]. On the other hand, studies on a family of gold(I) NHC complexes containing 1,3-substituted imidazole-2-ylidene or benzimidazole-2-ylidene and chloro or 2-pyrimidinethiolato ligands revealed that halogen derivatives 64 and 66 (Figure 3) were less effective in inhibiting TrxR (IC50 values against isolated TrxR1 of 0.7 and 0.205 nM, respectively) compared to the corresponding thiolato complexes 65 and 67 (Figure 3) (IC50 values against isolated TrxR1 of 0.062 and 0.0184 nM, respectively), and this difference in hampering selenoenzyme activity was consistent with a reduced cytotoxic potential [52]. Overall, the majority of the above-listed gold(I) complexes have been proven to inhibit TrxR1 much more effectively than TrxR2 in vitro. However, some cationic gold(I) compounds, owing to their ability to accumulate inside mitochondria as a result of the high mitochondrial membrane potential (Δψm), have been proven to specifically inhibit TrxR2 in cells [53].
In addition to gold(I) complexes, gold(III) species have also attracted attention as TrxR inhibitors. Compounds belonging to this class exhibit a high in vitro anticancer effect due to TrxR inhibition, the latter occurring either by oxidation of key enzyme residues or by gold coordination to the C-terminal active site [26]. Among them, organogold(III) complexes with diamine ligands AuBiPy, AuXil and AuPy (68–70, Figure 4) were demonstrated to be inhibitors of isolated TrxR2 at low- or sub-micromolar doses (IC50 values of 0.28, 0.21 and 1.42 µM, respectively), and this inhibition was related to their cytotoxicity towards human cancer cells [54,55]. Engman and co-authors, described some organogold(III) complexes as very effective in inhibiting TrxR in vitro (IC50 values in the nanomolar range), but lacking any significant anticancer activity in cells and in in vivo xenograft models [56]. On the contrary, gold(III) dithiocarbamato complexes 71 and 72 (Figure 4) were shown to inhibit TrxR in prostate cancer cells at low micromolar doses and possess a high antitumor activity, both in vitro and in vivo [57]. Furthermore, the proteasome has been identified as a major in vitro and in vivo target of these complexes, thus suggesting that the antitumor efficacy possibly can be mediated by multitargeted mechanisms. Similarly, a gold(III) complex with 2-acetylpyridine-N(4)-ortho-chlorophenyl-thiosemicarbazone (73, Figure 4) was proven to be very effective in hampering TrxR activity (in vitro IC50 of 0.23 µM) [58]. By comparing the TrxR inhibition results with those of the cytotoxicity studies, however, a correlation could not be established, and the cytotoxic profile of the compound seems to mainly be the result of the coordination of thiosemicarbazone ligand. Recently, a series of phosphorescent (2-phenyl)pyridine gold(III) 2,4,6-tris(trifluoromethyl) phenyl Complexes 74–79 (Figure 4) were investigated by Rubbiani and co-authors [59]. These complexes showed a moderate TrxR inhibition, with IC50 values in the micromolar range (1.02–22.9 µM). Interestingly, most of the Au(III) compounds displayed a significantly lower activity towards GR. Nevertheless, no direct correlation could be drawn looking at cytotoxicity and TrxR inhibition activities, the most effective TrxR inhibitor Compound 76 (in vitro IC50 of 1.02 µM) being less cytotoxic compared to the weaker TrxR inhibitor 75 (in vitro IC50 of 1.43 µM). In addition, a DNA binding ability was suggested to contribute to their cellular effects. Overall, the studies performed so far on gold(III) complexes underlined that this class of derivatives acts through a multitargeted mechanism that involves interactions with molecular targets other than TrxR inhibition [60,61,62].

3. Platinum-Based Inhibitors

The cytotoxic effect of cisplatin (cis-diamminedichloroplatinum(II) (CDDP), 80; Figure 5), the milestone of metal-based drugs in cancer chemotherapy, is generally considered to be attributed to the formation of DNA-platinum adducts, causing cell cycle arrest and triggering of apoptosis [63]. However, since only a very small fraction of the intracellular CDDP has been found to react with genomic DNA, other biological targets have been proposed to take part, accounting for the cytotoxic effects observed [64]. Since the active metabolites of cisplatin are strong electrophiles, they can also react with nucleophiles other than DNA, such as RNA or nucleophilic moieties of proteins. Of specific interest are the numerous pieces of evidence showing that interactions with the intracellular disulfide/dithiol systems may account for some of the cytotoxic effects exerted by cisplatin. In this respect, the Sec residue of selenoproteins may represent a major target [65]. In accordance, it has been shown that an increase in Trx system activity contributes to cancer cell resistance to CDDP [10,22], and that at concentrations ranging in the micromolar range, CDDP possesses TrxR inhibitory activity [66]. Interestingly, CDDP has no effect on oxidized TrxR, E. coli TrxR, engineered Sec498Cys mutant TrxR, nor on GR, thus suggesting that its mechanism of inhibition most likely involves coordination of platinum to the Sec-containing redox center [65,67,68]. In addition, carboplatin (cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II), 81, Figure 5) and oxaliplatin ([(1R,2R)-cyclohexane-1,2-diamine](ethanedioato-O,O′)platinum(II), 82, Figure 5) were also found to be effective inhibitors of isolated TrxR at the micromolar level [68]. Yet again, both Pt(II) derivatives exerted a superior inhibition of TrxR over the related flavoprotein enzyme GR.
In recent years, Becker et al. evaluated a series of platinum(II) terpyridine Complexes 83–92 (Figure 5), known for their well-documented DNA-intercalating activity [69], as TrxR inhibitors. Notably, all complexes were capable of accomplishing an irreversible TrxR inhibition in a dose-dependent manner, eliciting low nanomolar IC50 values in a cell-free system and low micromolar concentrations in cancer cells [70]. Similarly, other authors designed and developed novel platinum(II) terpyridine and nitrofuran complexes able to hamper the activity of isolated human TrxR1 in the nM range [27,71,72]. All together, these studies suggest that the cytotoxic properties of these classes of derivatives are likely to result from both DNA interaction and other mechanisms of action, possibly involving a specific and irreversible TrxR inhibition.
Molecules 20 12732 g004 550
Figure 4. Structures of gold(III)-based inhibitors.
Figure 4. Structures of gold(III)-based inhibitors.
Molecules 20 12732 g004
Molecules 20 12732 g005 550
Figure 5. Structures of platinum(II)-based inhibitors.
Figure 5. Structures of platinum(II)-based inhibitors.
Molecules 20 12732 g005

4. Silver-Based Inhibitors

Even though silver has been used as colloidal material for many years, only recent advances in synthesis and characterization techniques have led to this metal being incorporated into many metal complexes for drug development purposes. Silver complexes, which have been widely studied as anti-infectives in the last decade, have recently been proposed as potential anticancer agents [73]. Given the knowledge that exposure to Ag leads to the accumulation of Ag2Se in mammals [74] and keeping in mind the reactivity of Sec residues toward electrophilic compounds, we recently evaluated some silver(I) complexes as TrxR inhibitors 93–95 (Figure 6) and compared their activity with those elicited by their gold(I) parent compounds [44,75]. Like their corresponding gold(I) complexes, the silver(I) derivatives were effective in inhibiting 50% of isolated TrxR1 activity at nanomolar concentrations. Remarkably, the cytotoxic effects induced by Ag(I) complexes were slightly higher than those elicited by corresponding Au(I) complexes. Furthermore, the silver(I)-NHC derivative 94 showed a preferential cytotoxic activity vs. neoplastic cells. Similar results were later obtained by Rigobello and co-workers by comparing some silver(I)- and gold(I)-NHC complexes bearing a fluorescent anthracenyl ligand (96, Figure 6) [76]. In this report, the dimerization of peroxiredoxin 3 was also observed, thus demonstrating the ability of the silver compound to reach the mitochondrial compartment. Subsequently, we reported on a water-soluble sulfonate-functionalized silver(I) NHC 97 with a significant in vitro antiproliferative activity (in the sub-micromolar range) that was correlated with its strong ability to inhibit TrxR [77]. The inhibition of this selenoenzyme induced by Compound 97 (Figure 6) consistently determined an alteration of the cellular redox environment, thus leading to the induction of apoptotic cell death through the activation of the ASK-1 pathway. Even though, at present, mechanistic aspects concerning the mode of inhibition are still lacking, taken together, these studies validate the hypothesis of TrxR as a protein target for silver(I) in addition to gold(I) complexes.

5. Ruthenium-Based Inhibitors

Ruthenium-based compounds have emerged in recent years as potential candidates for cancer treatment. Currently, the Ru(III) complex NAMI-A, [H2im][trans-Ru(III)Cl4-(DMSO-S)(Him)] (Him = imidazole, 98; Figure 6) and KP1019 ([H2ind][trans-Ru(III)Cl4(Hind)2] (Hind = indazole, 99; Figure 6) have recently entered clinical trials [78,79]. Concerning their mechanism of action, many studies have demonstrated that Ru complexes exert their antiproliferative activities primarily through interaction with DNA and with different cellular proteins [80]. Among them, TrxR has also been proposed as a molecular target for this class of complexes. Actually, Ru complexes could inhibit TrxR activity due to the “soft” character of the Ru center. Messori and co-workers originally reported on a series of ruthenium(III) compounds able to inhibit TrxR. Based on the structure of NAMI-A, they synthesized some “tetrachlororuthenate” Ru(III) Compounds 100–102 (Figure 6) [81]. However, compared to gold- or platinum-containing complexes, these ruthenium(III) complexes were significantly less potent in inhibiting TrxR1, showing IC50 values in the micromolar range, and were not effective against mitochondrial TrxR2 isoform. A year later, the same authors reported a series of ruthenium(II)–arene compounds as inhibitors of TrxR [82]. Among them, the most efficacious derivative 103 (Figure 6) elicited an inhibition of 50% TrxR activity at low micromolar concentrations, with IC50 values of 4.6 μM and 14.7 μM for TrxR1 and TrxR2, respectively. In the search of some preliminary SARs, the authors pointed out that the higher the steric hindrance effect of the arene moiety, the lower the observed inhibitory potency of TrxR was, indicating that bulky substituents in the arene ligand interfered with the effective interaction between the compounds and the enzyme. Nevertheless, the authors concluded that these derivatives behave much more as inhibitors of cathepsin B rather than TrxR inhibitors. Likewise, Ott and co-workers described some arene Ru(II) complexes 104–107 (Figure 6) endowed with TrxR and cathepsin B inhibitory activity at micromolar range [83]. These authors indicated a preference of their compounds for the inhibition of the selenoenzyme TrxR compared to the cysteine-rich cathepsin B, with the IC50 calculated for TrxR being up to 50-times lower compared with those calculated for cathepsin B. Accordingly, the cytotoxic effects on tumor cell growth were accompanied by an appropriate decrease in cell impedance and cellular respiration. The studied complexes were, however, also able to efficiently bind to BSA and DNA, thus pointing out that their in vitro antiproliferative activity might be based on a multitargeted mechanism. Later, Luo and co-workers prepared a series of Ru(II) polypyridyl complexes with diimine ligands 108–111 (Figure 6), and their interaction with TrxR was examined [84]. Despite these complexes showing the ability to inhibit TrxR at micromolar concentrations, their cytotoxic potency were significantly lower compared to that of cisplatin.
Molecules 20 12732 g006 550
Figure 6. Structures of silver-based and ruthenium-based inhibitors.
Figure 6. Structures of silver-based and ruthenium-based inhibitors.
Molecules 20 12732 g006

6. Other Metal-Containing Inhibitors

Motexafin gadolinium (MGd, 112; Figure 7) is a porphyrin-like molecule utilized in cancer therapies [85]. MGd is currently in clinical trials, both as a single drug and in combination with other chemotherapeutics or with radiotherapy for the treatment of different types of cancers, including non-small cell lung, brain, renal, pancreatic and biliary carcinomas and lymphoma. The anticancer activity of this compound has been correlated with its ability to undergo redox cycling and to generate superoxide and other ROS under aerobic conditions causing oxidative stress. MGd is also able to catalyze the oxidation of intracellular reducing metabolites, such as NADPH, GSH, ascorbic acid and protein vicinal thiols [85]. It has further been shown to induce cytotoxicity in multiple myeloma cell lines by altering the cellular redox state due to an increased production of ROS [86]. In 2006, the effects of MGd on cancer cells’ redox state was associated with its ability to interact with TrxR [87]. Holmgren and co-workers showed that MGd is capable of interacting with TrxR1 and of generating ROS, such as superoxide and hydrogen peroxide. In addition, however, in the same study, the authors demonstrated that it also acts as a potent inhibitor of ribonucleotide reductase, a cellular enzyme essential for DNA synthesis.
Recently, the group of Prof. Ott, through a virtual screening study for active TrxR inhibitors, selected the tin(IV) organometallic compound NIH 643845 (113, Figure 7) as one of the most active compounds. Based on the virtual screening findings, they thought it of interest to provide a “proof of concept” for the involvement of TrxR inhibition in the antitumor activity of tin(IV) species [88]. Accordingly, they studied the effects on TrxR of a series of benzoate tin organometallics related to Compound 113 and laid down some preliminary, but fundamental, SARs. All n-butyltin(IV) complexes 114–127 (Figure 7) inhibited TrxR with IC50 values in the micromolar range, the most active derivatives eliciting IC50 values in the low micromolar range (1–5 µM). It is important to mention that TrxR inhibitory activity was partially modulated by variation of the substituents on the benzoate ligands. Among all derivatives, tri-n-butyltin carboxylates (114–117) were on average weaker inhibitors (in vitro IC50 values in the 5.88–67.16 µM range) than the respective di-n-butyl derivatives (118–127) (in vitro IC50 values in the 1.37–17.59 µM range), and among the latter, N-acetylated derivatives 124–127 (in vitro IC50 values in the 1.37–4.70 µM range) were more active than complexes with a free or methylated amino group, 121–123 (in vitro IC50 values in the 10.41–16.05 µM range). The authors attributed these differences to the presence of an amide bond in the N-acetylated derivatives, which can decrease the electron density of the carboxylate groups, thus destabilizing their coordination to tin and ultimately resulting in stronger inhibition of TrxR. On the other hand, the position of the substituents on the aromatic rings was shown not to influence the TrxR inhibitory activity. As reference compounds, they used the di-n-butyltin(IV) oxide and the tri-n-butyltin(IV) chloride. The former was proven completely ineffective, whereas the latter exhibited similar activity to the carboxylates. On these bases, the authors suggested the presence of an appropriate leaving group (a chloride or a carboxylate) as an essential requirement for obtaining an effective tin(IV)-based TrxR inhibitor. However, substantial differences in TrxR hampering ability did not always confer a huge difference in the cell growth inhibitory effects against cancer cell lines, the less efficient TrxR inhibitor being derivative 117 (Figure 7) and the more cytotoxic than the most effective at hampering TrxR being derivative 124 (Figure 7) (TrxR IC50 values of 67.16 and 1.37 µM, respectively; IC50 against MCF-7 cells of 0.13 and 0.60 µM, respectively).
Subsequently, the same authors prepared a series of organotin(IV) carboxylate complexes 128–139 (Figure 7) with naphthalimide-, citraconimide- or maleimide-derived ligands. As TrxR inhibitors, three of the four newly prepared maleimide derivatives were more effective compared with both citraconimide- and naphthalimide-containing compounds, eliciting IC50 values in the 2.3–11.3 µM range [89]. Even though all of these compounds showed a TrxR inhibitory activity at µM concentrations and some SARs were tentatively drawn, again, no clear correlation was established between TrxR inhibition and cytotoxicity potency, thus indicating that inhibition of TrxR is unlikely the main mode of action of these compounds.
Molecules 20 12732 g007 550
Figure 7. Structures of other metal-based inhibitors.
Figure 7. Structures of other metal-based inhibitors.
Molecules 20 12732 g007

7. Semimetal-Based Inhibitors

The use in medicinal chemistry of tellurium, in the form of 2 KTeO32−, started during the 1930s with the work of Sir Alexander Fleming, who reported that it was an effective antibiotic able to act even in penicillin-resistant bacteria [90]. However, its potential as an anticancer agent is relatively unexplored.
Engman and co-workers synthesized several organotellurium compounds, where Te is in the +IV oxidation state, including water-soluble organotellurium compounds (diaryl tellurides, alkyl aryl tellurides and dialkyl tellurides), tellurium analogues of vitamin E, organotellurium steroids, lipids, amino acids, nucleic bases and polyamine inhibitors, as well as cyclodextrin-derived diorganyl tellurides [91,92,93,94], and studied their interaction with TrxR. Notably, some of these organotellurium derivatives inhibited the isolated enzyme at sub- or low micromolar levels. However, their TrxR inhibition did not correlate well with their cytotoxicity.
Recently, the group of Prof. Holmgren has demonstrated that arsenic trioxide (ATO) is a potent inhibitor of TrxR [95]. ATO has been used for several centuries in traditional medicine for curing cancers, and recently, it has been shown to be very effective in the treatment of both leukemia [96,97,98,99], and solid tumors [100]. In fact, in 2010, the FDA approved it for the treatment of acute promyelocytic leukemia. Past evidence indicated protein sulfhydryl groups as the main targets of the drug [100]. On the other hand, a mechanism involving a strong and irreversible inhibition of mammalian TrxR, involving both the C-terminal and N-terminal redox active sites of the enzyme, was recognized by Holmgren and co-workers. Notably, the inhibition of TrxR in breast cancer cells subsequently resulted in the inactivation of the Trx system and, ultimately, the induction of cell death.

8. Concluding Remarks

Since the discovery of TrxR inhibition by auranofin, great interest in the metal-containing compounds as TrxR inhibitors has emerged. Among all, gold(I) complexes are the most effective inhibitors of mammalian TrxRs known today. However, in recent years, many highly promising novel metal-based species have been described, which we herein have tried to briefly summarize as an attempt to give a general overview of the current development in the field. Several of these metal- and semimetal-based compounds have been shown to inhibit TrxR, and the anticancer potential of such compounds continues to be the subject of considerable research. As already mentioned, TrxR is strongly associated with tumor proliferation and tumor aggressiveness. It is further known to be upregulated in many tumors and linked to drug resistance. It is therefore not surprising that TrxR is believed to be a promising target for cancer therapy, and therefore, more extensive investigations are needed.
Clinically-approved platinum drugs have also been proven to exert their antitumor activity, not only through the interaction with DNA, but also by TrxR inhibition. Among metal-based derivatives, silver(I) complexes have emerged as very effective in TrxR inhibition. Owing to their selectivity towards cancer cells, they represent a very promising class of anticancer agents and deserve to be further examined. Actually, mechanistic studies proving Ag fragment binding to TrxR and the discovery of a silver(I) drug target site of TrxR are still lacking and are indeed warranted. Similarly, tin(IV) organometallic compounds show extraordinary anticancer properties, being able to selectively target TrxR. More in vitro and in vivo studies are nonetheless needed in order to fully elucidate the potential of these new classes of TrxR inhibitors for the development of new chemotherapeutic drugs.
Overall, however, some general considerations have to be underlined concerning metal complexes as TrxR inhibitors. The metal center has emerged as fundamental to achieve the inhibition of the TrxR enzymes, thus supporting the assumption of the preferential binding to the Sec residue present in the active site of TrxR. Nevertheless, it should be mentioned that a direct correlation between TrxR inhibition and cytotoxic effects of metal complexes could not always be claimed, and this indicates that other mechanisms besides TrxR inhibition may contribute to the overall pharmacological profile. In particular, structural modifications of metal complexes through the modulation of ligand physicochemical characteristics, as well as of the stability/lability of the coordinative bonds lead to major changes in the biological activity, pharmacodynamic properties and cellular bioavailability. Hence, through an accurate choice of the ligands, a fine tuning of the pharmacological profile can be accomplished. Based on these considerations, however, a key issue in the development of metal complexes as TrxR inhibitors is the evaluation of enzyme inhibition also in intact cells, since cell-free studies can be misleading and do not fully reflect their pharmacological potential.
Almost totally unexplored is, at present, the potential of semimetal compounds as anticancer agents targeting TrxR. The few reports on organotellurium derivatives, despite being very promising, are lacking both mechanistic and SAR aspects, thus pointing out that further studies are required to gain more insight into the development of semimetal-based derivatives as TrxR inhibitors. In addition, as several different splice variants and isoforms of both TrxR1 and TrxR2 have been characterized, more research effort is required to understand their specific role in tumor development and resistance. Increased knowledge will undoubtedly enable more accurate and effective drug development.

Acknowledgments

This article has been financially supported by The Swedish Cancer Society (Cancerfonden) and the University of Padova (Progetto di Ateneo CPDA131114/13).

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Groitl, B.; Jakob, U. Thiol-based redox switches. Biochim. Biophys. Acta 2014, 1844, 1335–1343. [Google Scholar] [CrossRef] [PubMed]
  2. Gromer, S.; Urig, S.; Becker, K. The thioredoxin system—From science to clinic. Med. Res. Rev. 2004, 24, 40–89. [Google Scholar] [CrossRef] [PubMed]
  3. Arner, E.S. Focus on mammalian thioredoxin reductases—Important selenoproteins with versatile functions. Biochim. Biophys. Acta 2009, 1790, 495–526. [Google Scholar] [CrossRef] [PubMed]
  4. Jeong, W.; Yoon, H.W.; Lee, S.R.; Rhee, S.G. Identification and characterization of TRP14, a thioredoxin-related protein of 14 kDa. New insights into the specificity of thioredoxin function. J. Biol. Chem. 2004, 279, 3142–3150. [Google Scholar] [CrossRef] [PubMed]
  5. Nordberg, J.; Arnér, E.S. Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. Free Radic. Biol. Med. 2001, 31, 1287–1312. [Google Scholar] [CrossRef]
  6. Toyokuni, S.; Okamoto, K.; Yodoi, J.; Hiai, H. Persistent oxidative stress in cancer. FEBS Lett. 1995, 358, 1–3. [Google Scholar] [CrossRef]
  7. Schumacker, P.T. Reactive oxygen species in cancer cells: Live by the sword, die by the sword. Cancer Cell 2006, 10, 175–176. [Google Scholar] [CrossRef] [PubMed]
  8. Trachootham, D.; Alexandre, J.; Huang, P. Targeting cancer cells by ROS-mediated mechanisms: A radical therapeutic approach? Nat. Rev. Drug Discov. 2009, 8, 579–591. [Google Scholar] [CrossRef] [PubMed]
  9. Nguyen, P.; Awwad, R.T.; Smart, D.D.; Spitz, D.R.; Gius, D. Thioredoxin reductase as a novel molecular target for cancer therapy. Cancer Lett. 2006, 236, 164–174. [Google Scholar] [CrossRef] [PubMed]
  10. Eriksson, S.E.; Prast-Nielsen, S.; Flaberg, E.; Szekely, L.; Arner, E.S. High levels of thioredoxin reductase 1 modulate drug-specific cytotoxic efficacy. Free Radic. Biol. Med. 2009, 47, 1661–1671. [Google Scholar] [CrossRef] [PubMed]
  11. Grogan, T.M.; Fenoglio-Prieser, C.; Zeheb, R.; Bellamy, W.; Frutiger, Y.; Vela, E.; Stemmerman, G.; Macdonald, J.; Richter, L.; Gallegos, A.; et al. Thioredoxin, a putative oncogene product, is overexpressed in gastric carcinoma and associated with increased proliferation and increased cell survival. Hum. Pathol. 2000, 31, 475–481. [Google Scholar] [CrossRef] [PubMed]
  12. Raffel, J.; Bhattacharyya, A.K.; Gallegos, A.; Cui, H.; Einspahr, J.G.; Alberts, D.S.; Powis, G. Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival. J. Lab. Clin. Med. 2003, 142, 46–51. [Google Scholar] [CrossRef] [PubMed]
  13. Rabik, C.A.; Dolan, M.E. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat. Rev. 2007, 33, 9–23. [Google Scholar] [CrossRef] [PubMed]
  14. Penney, R.B.; Roy, D. Thioredoxin-mediated redox regulation of resistance to endocrine therapy in breast cancer. Biochim. Biophys. Acta 2013, 1836, 60–79. [Google Scholar] [CrossRef] [PubMed]
  15. Liu, Y.; Li, Y.; Yu, S.; Zhao, G. Recent advances in the development of thioredoxin reductase inhibitors as anticancer agents. Curr. Drug Targets 2012, 13, 1432–1444. [Google Scholar] [CrossRef] [PubMed]
  16. Saccoccia, F.; Angelucci, F.; Boumis, G.; Carotti, D.; Desiato, G.; Miele, A.E.; Bellelli, A. Thioredoxin reductase and its inhibitors. Curr. Protein Pept. Sci. 2014, 15, 621–646. [Google Scholar] [CrossRef] [PubMed]
  17. Hill, K.E.; McCollum, G.W.; Boeglin, M.E.; Burk, R.F. Thioredoxin reductase activity is decreased by selenium deficiency. Biochem. Biophys. Res. Commun. 1997, 234, 293–295. [Google Scholar] [CrossRef] [PubMed]
  18. Gromer, S.; Arscott, L.D.; Williams, C.H., Jr.; Schirmer, R.H.; Becker, K. Human placenta thioredoxin reductase. Isolation of the selenoenzyme, steady state kinetics, and inhibition by therapeutic gold compounds. J. Biol. Chem. 1998, 273, 20096–20101. [Google Scholar] [CrossRef] [PubMed]
  19. Rigobello, M.P.; Scutari, G.; Boscolo, R.; Bindoli, A. Induction of mitochondrial permeability transition by auranofin, a gold(I)-phosphine derivative. Br. J. Pharmacol. 2002, 136, 1162–1168. [Google Scholar] [CrossRef] [PubMed]
  20. Rigobello, M.P.; Scutari, G.; Folda, A.; Bindoli, A. Mitochondrial thioredoxin reductase inhibition by gold(I) compounds and concurrent stimulation of permeability transition and release of cytochrome c. Biochem. Pharmacol. 2004, 67, 689–696. [Google Scholar] [CrossRef] [PubMed]
  21. Rigobello, M.P.; Folda, A.; Dani, B.; Menabo, R.; Scutari, G.; Bindoli, A. Gold(I) complexes determine apoptosis with limited oxidative stress in Jurkat T cells. Eur. J. Pharmacol. 2008, 582, 26–34. [Google Scholar] [CrossRef] [PubMed]
  22. Marzano, C.; Gandin, V.; Folda, A.; Scutari, G.; Bindoli, A.; Rigobello, M.P. Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells. Free Radic. Biol. Med. 2007, 42, 872–881. [Google Scholar] [CrossRef] [PubMed]
  23. Chaudiere, J.; Tappel, A.L. Interaction of gold(I) with the active site of selenium-glutathione peroxidase. J. Inorg. Biochem. 1984, 20, 313–325. [Google Scholar] [CrossRef]
  24. Urig, S.; Fritz-Wolf, K.; Reau, R.; Herold-Mende, C.; Toth, K.; Davioud-Charvet, E.; Becker, K. Undressing of phosphine gold(I) complexes as irreversible inhibitors of human disulfide reductases. Angew. Chem. Int. Ed. 2006, 45, 1881–1886. [Google Scholar] [CrossRef] [PubMed]
  25. Saccoccia, F.; Angelucci, F.; Boumis, G.; Brunori, M.; Miele, A.E.; Williams, D.L.; Bellelli, A. On the mechanism and rate of gold incorporation into thiol-dependent flavoreductases. J. Inorg. Biochem. 2012, 108, 105–111. [Google Scholar] [CrossRef] [PubMed]
  26. Pratesi, A.; Gabbiani, C.; Ginanneschi, M.; Messori, L. Reactions of medicinally relevant gold compounds with the C-terminal motif of thioredoxin reductase elucidated by MS analysis. Chem. Commun. 2010, 46, 7001–7003. [Google Scholar] [CrossRef] [PubMed]
  27. Millet, R.; Urig, S.; Jacob, J.; Amtmann, E.; Moulinoux, J.P.; Gromer, S.; Becker, K.; Davioud-Charvet, E. Synthesis of 5-nitro-2-furancarbohydrazides and their cis-diamminedichloroplatinum complexes as bitopic and irreversible human thioredoxin reductase inhibitors. J. Med. Chem. 2005, 48, 7024–7039. [Google Scholar] [CrossRef] [PubMed]
  28. Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. Available online: https://clinicaltrials.gov/show/NCT01747798 (accessed on 8 July 2015).
  29. Meyers, S. “Concierge” medicine. Who really pays for gold standard access to doctors? Trustee 2003, 56, 12–14. [Google Scholar] [PubMed]
  30. Christodoulou, J.; Sadler, P.J.; Tucker, A. A new structural transition of serum albumin dependent on the state of Cys34. Detection by 1H-NMR spectroscopy. Eur. J. Biochem. 1994, 225, 363–368. [Google Scholar] [CrossRef] [PubMed]
  31. Roberts, J.R.; Xiao, J.; Schliesman, B.; Parsons, D.J.; Shaw, C.F., III. Kinetics and Mechanism of the Reaction between Serum Albumin and Auranofin (and Its Isopropyl Analogue) in Vitro. Inorg. Chem. 1996, 35, 424–433. [Google Scholar] [CrossRef] [PubMed]
  32. Gandin, V.; Fernandes, A.P.; Rigobello, M.P.; Dani, B.; Sorrentino, F.; Tisato, F.; Björnstedt, M.; Bindoli, A.; Sturaro, A.; Rella, R.; et al. Cancer cell death induced by phosphine gold(I) compounds targeting thioredoxin reductase. Biochem. Pharmacol. 2010, 79, 90–101. [Google Scholar] [CrossRef] [PubMed]
  33. Ott, I.; Qian, X.; Xu, Y.; Vlecken, D.H.; Marques, I.J.; Kubutat, D.; Will, J.; Sheldrick, W.S.; Jesse, P.; Prokop, A.; et al. A gold(I) phosphine complex containing a naphthalimide ligand functions as a TrxR inhibiting antiproliferative agent and angiogenesis inhibitor. J. Med. Chem. 2009, 52, 763–770. [Google Scholar] [CrossRef] [PubMed]
  34. Viry, E.; Battaglia, E.; Deborde, V.; Muller, T.; Reau, R.; Davioud-Charvet, E.; Bagrel, D. A sugar-modified phosphole gold complex with antiproliferative properties acting as a thioredoxin reductase inhibitor in MCF-7 cells. ChemMedChem 2008, 3, 1667–1670. [Google Scholar] [CrossRef] [PubMed]
  35. Jortzik, E.; Farhadi, M.; Ahmadi, R.; Toth, K.; Lohr, J.; Helmke, B.M.; Kehr, S.; Unterberg, A.; Ott, I.; Gust, R.; et al. Antiglioma activity of GoPI-sugar, a novel gold(I)-phosphole inhibitor: Chemical synthesis, mechanistic studies, and effectiveness in vivo. Biochim. Biophys. Acta 2014, 1844, 1415–1426. [Google Scholar] [CrossRef] [PubMed]
  36. Serebryanskaya, T.V.; Lyakhov, A.S.; Ivashkevich, L.S.; Schur, J.; Frias, C.; Prokop, A.; Ott, I. Gold(I) thiotetrazolates as thioredoxin reductase inhibitors and antiproliferative agents. Dalton Trans. 2015, 44, 1161–1169. [Google Scholar] [CrossRef] [PubMed]
  37. Vergara, E.; Casini, A.; Sorrentino, F.; Zava, O.; Cerrada, E.; Rigobello, M.P.; Bindoli, A.; Laguna, M.; Dyson, P.J. Anticancer therapeutics that target selenoenzymes: Synthesis, characterization, in vitro cytotoxicity, and thioredoxin reductase inhibition of a series of gold(I) complexes containing hydrophilic phosphine ligands. ChemMedChem 2010, 5, 96–102. [Google Scholar] [CrossRef] [PubMed]
  38. Ortego, L.; Cardoso, F.; Martins, S.; Fillat, M.F.; Laguna, A.; Meireles, M.; Villacampa, M.D.; Gimeno, M.C. Strong inhibition of thioredoxin reductase by highly cytotoxic gold(I) complexes. DNA binding studies. J. Inorg. Biochem. 2014, 130, 32–37. [Google Scholar] [CrossRef] [PubMed]
  39. Lessa, J.A.; Guerra, J.C.; de Miranda, L.F.; Romeiro, C.F.; Da Silva, J.G.; Mendes, I.C.; Speziali, N.L.; Souza-Fagundes, E.M.; Beraldo, H. Gold(I) complexes with thiosemicarbazones: Cytotoxicity against human tumor cell lines and inhibition of thioredoxin reductase activity. J. Inorg. Biochem. 2011, 105, 1729–1739. [Google Scholar] [CrossRef] [PubMed]
  40. Galassi, R.; Burini, A.; Ricci, S.; Pellei, M.; Rigobello, M.P.; Citta, A.; Dolmella, A.; Gandin, V.; Marzano, C. Synthesis and characterization of azolate gold(I) phosphane complexes as thioredoxin reductase inhibiting antitumor agents. Dalton Trans. 2012, 41, 5307–5318. [Google Scholar] [CrossRef] [PubMed]
  41. Rackham, O.; Nichols, S.J.; Leedman, P.J.; Berners-Price, S.J.; Filipovska, A. A gold(I) phosphine complex selectively induces apoptosis in breast cancer cells: Implications for anticancer therapeutics targeted to mitochondria. Biochem. Pharmacol. 2007, 74, 992–1002. [Google Scholar] [CrossRef] [PubMed]
  42. Wetzel, C.; Kunz, P.C.; Kassack, M.U.; Hamacher, A.; Bohler, P.; Watjen, W.; Ott, I.; Rubbiani, R.; Spingler, B. Gold(I) complexes of water-soluble diphos-type ligands: Synthesis, anticancer activity, apoptosis and thioredoxin reductase inhibition. Dalton Trans. 2011, 40, 9212–9220. [Google Scholar] [CrossRef] [PubMed]
  43. Wang, Y.; Liu, M.; Cao, R.; Zhang, W.; Yin, M.; Xiao, X.; Liu, Q.; Huang, N. A soluble bis-chelated gold(I) diphosphine compound with strong anticancer activity and low toxicity. J. Med. Chem. 2013, 56, 1455–1466. [Google Scholar] [CrossRef] [PubMed]
  44. Santini, C.; Pellei, M.; Papini, G.; Morresi, B.; Galassi, R.; Ricci, S.; Tisato, F.; Porchia, M.; Rigobello, M.P.; Gandin, V.; et al. In vitro antitumour activity of water soluble Cu(I), Ag(I) and Au(I) complexes supported by hydrophilic alkyl phosphine ligands. J. Inorg. Biochem. 2011, 105, 232–240. [Google Scholar] [CrossRef] [PubMed]
  45. Lupidi, G.; Avenali, L.; Bramucci, M.; Quassinti, L.; Pettinari, R.; Khalife, H.K.; Gali-Muhtasib, H.; Marchetti, F.; Pettinari, C. Synthesis, properties, and antitumor effects of a new mixed phosphine gold(I) compound in human colon cancer cells. J. Inorg. Biochem. 2013, 124, 78–87. [Google Scholar] [CrossRef] [PubMed]
  46. Meyer, A.; Bagowski, C.P.; Kokoschka, M.; Stefanopoulou, M.; Alborzinia, H.; Can, S.; Vlecken, D.H.; Sheldrick, W.S.; Wolfl, S.; Ott, I. On the biological properties of alkynyl phosphine gold(I) complexes. Angew. Chem. Int. Ed. 2012, 51, 8895–8899. [Google Scholar] [CrossRef] [PubMed]
  47. Hickey, J.L.; Ruhayel, R.A.; Barnard, P.J.; Baker, M.V.; Berners-Price, S.J.; Filipovska, A. Mitochondria-targeted chemotherapeutics: The rational design of gold(I) N-heterocyclic carbene complexes that are selectively toxic to cancer cells and target protein selenols in preference to thiols. J. Am. Chem. Soc. 2008, 130, 12570–12571. [Google Scholar] [CrossRef] [PubMed]
  48. Rubbiani, R.; Kitanovic, I.; Alborzinia, H.; Can, S.; Kitanovic, A.; Onambele, L.A.; Stefanopoulou, M.; Geldmacher, Y.; Sheldrick, W.S.; Wolber, G.; et al. Benzimidazol-2-ylidene gold(I) complexes are thioredoxin reductase inhibitors with multiple antitumor properties. J. Med. Chem. 2010, 53, 8608–8618. [Google Scholar] [CrossRef] [PubMed]
  49. Rubbiani, R.; Can, S.; Kitanovic, I.; Alborzinia, H.; Stefanopoulou, M.; Kokoschka, M.; Monchgesang, S.; Sheldrick, W.S.; Wolfl, S.; Ott, I. Comparative in vitro evaluation of N-heterocyclic carbene gold(I) complexes of the benzimidazolylidene type. J. Med. Chem. 2011, 54, 8646–8657. [Google Scholar] [CrossRef] [PubMed]
  50. Rubbiani, R.; Salassa, L.; de Almeida, A.; Casini, A.; Ott, I. Cytotoxic gold(I) N-heterocyclic carbene complexes with phosphane ligands as potent enzyme inhibitors. ChemMedChem 2014, 9, 1205–1210. [Google Scholar] [CrossRef] [PubMed]
  51. Meyer, A.; Oehninger, L.; Geldmacher, Y.; Alborzinia, H.; Wolfl, S.; Sheldrick, W.S.; Ott, I. Gold(I) N-heterocyclic carbene complexes with naphthalimide ligands as combined thioredoxin reductase inhibitors and DNA intercalators. ChemMedChem 2014, 9, 1794–1800. [Google Scholar] [CrossRef] [PubMed]
  52. Schuh, E.; Pfluger, C.; Citta, A.; Folda, A.; Rigobello, M.P.; Bindoli, A.; Casini, A.; Mohr, F. Gold(I) carbene complexes causing thioredoxin 1 and thioredoxin 2 oxidation as potential anticancer agents. J. Med. Chem. 2012, 55, 5518–5528. [Google Scholar] [CrossRef] [PubMed]
  53. Rackham, O.; Shearwood, A.M.; Thyer, R.; McNamara, E.; Davies, S.M.; Callus, B.A.; Miranda-Vizuete, A.; Berners-Price, S.J.; Cheng, Q.; Arner, E.S.; et al. Substrate and inhibitor specificities differ between human cytosolic and mitochondrial thioredoxin reductases: Implications for development of specific inhibitors. Free Radic. Biol. Med. 2011, 50, 689–699. [Google Scholar] [CrossRef] [PubMed]
  54. Coronnello, M.; Mini, E.; Caciagli, B.; Cinellu, M.A.; Bindoli, A.; Gabbiani, C.; Messori, L. Mechanisms of cytotoxicity of selected organogold(III) compounds. J. Med. Chem. 2005, 48, 6761–6765. [Google Scholar] [CrossRef] [PubMed]
  55. Rigobello, M.P.; Messori, L.; Marcon, G.; Agostina Cinellu, M.; Bragadin, M.; Folda, A.; Scutari, G.; Bindoli, A. Gold complexes inhibit mitochondrial thioredoxin reductase: Consequences on mitochondrial functions. J. Inorg. Biochem. 2004, 98, 1634–1641. [Google Scholar] [CrossRef] [PubMed]
  56. Engman, L.; McNaughton, M.; Gajewska, M.; Kumar, S.; Birmingham, A.; Powis, G. Thioredoxin reductase and cancer cell growth inhibition by organogold(III) compounds. Anticancer Drugs 2006, 17, 539–544. [Google Scholar] [CrossRef] [PubMed]
  57. Cattaruzza, L.; Fregona, D.; Mongiat, M.; Ronconi, L.; Fassina, A.; Colombatti, A.; Aldinucci, D. Antitumor activity of gold(III)-dithiocarbamato derivatives on prostate cancer cells and xenografts. Int. J. Cancer 2011, 128, 206–215. [Google Scholar] [CrossRef] [PubMed]
  58. Parrilha, G.L.; Ferraz, K.S.; Lessa, J.A.; de Oliveira, K.N.; Rodrigues, B.L.; Ramos, J.P.; Souza-Fagundes, E.M.; Ott, I.; Beraldo, H. Metal complexes with 2-acetylpyridine-N(4)-orthochlorophenylthiosemicarbazone: Cytotoxicity and effect on the enzymatic activity of thioredoxin reductase and glutathione reductase. Eur. J. Med. Chem. 2014, 84, 537–544. [Google Scholar] [CrossRef] [PubMed]
  59. Rubbiani, R.; Zehnder, T.N.; Mari, C.; Blacque, O.; Venkatesan, K.; Gasser, G. Anticancer profile of a series of gold(III) (2-phenyl)pyridine complexes. ChemMedChem 2014, 9, 2781–2790. [Google Scholar] [CrossRef] [PubMed]
  60. Casini, A.; Hartinger, C.; Gabbiani, C.; Mini, E.; Dyson, P.J.; Keppler, B.K.; Messori, L. Gold(III) compounds as anticancer agents: Relevance of gold-protein interactions for their mechanism of action. J. Inorg. Biochem. 2008, 102, 564–575. [Google Scholar] [CrossRef] [PubMed]
  61. Casini, A.; Cinellu, M.A.; Minghetti, G.; Gabbiani, C.; Coronnello, M.; Mini, E.; Messori, L. Structural and solution chemistry, antiproliferative effects, and DNA and protein binding properties of a series of dinuclear gold(III) compounds with bipyridyl ligands. J. Med. Chem. 2006, 49, 5524–5531. [Google Scholar] [CrossRef] [PubMed]
  62. Ronconi, L.; Fregona, D. The Midas touch in cancer chemotherapy: From platinum- to gold-dithiocarbamato complexes. Dalton Trans. 2009, 10670–10680. [Google Scholar] [CrossRef] [PubMed]
  63. Todd, R.C.; Lippard, S.J. Inhibition of transcription by platinum antitumor compounds. Metallomics 2009, 1, 280–291. [Google Scholar] [CrossRef] [PubMed]
  64. Sancho-Martinez, S.M.; Prieto-Garcia, L.; Prieto, M.; Lopez-Novoa, J.M.; Lopez-Hernandez, F.J. Subcellular targets of cisplatin cytotoxicity: an integrated view. Pharmacol. Ther. 2012, 136, 35–55. [Google Scholar] [CrossRef] [PubMed]
  65. Prast-Nielsen, S.; Cebula, M.; Pader, I.; Arner, E.S. Noble metal targeting of thioredoxin reductase—Covalent complexes with thioredoxin and thioredoxin-related protein of 14 kDa triggered by cisplatin. Free Radic. Biol. Med. 2010, 49, 1765–1778. [Google Scholar] [CrossRef] [PubMed]
  66. Sasada, T.; Nakamura, H.; Ueda, S.; Sato, N.; Kitaoka, Y.; Gon, Y.; Takabayashi, A.; Spyrou, G.; Holmgren, A.; Yodoi, J. Possible involvement of thioredoxin reductase as well as thioredoxin in cellular sensitivity to cis-diamminedichloroplatinum (II). Free Radic. Biol. Med. 1999, 27, 504–514. [Google Scholar] [CrossRef]
  67. Arnér, E.S.; Nakamura, H.; Sasada, T.; Yodoi, J.; Holmgren, A.; Spyrou, G. Analysis of the inhibition of mammalian thioredoxin, thioredoxin reductase, and glutaredoxin by cis-diamminedichloroplatinum(II) and its major metabolite, the glutathione-platinum complex. Free Radic. Biol. Med. 2001, 31, 1170–1178. [Google Scholar] [CrossRef]
  68. Witte, A.B.; Anestål, K.; Jerremalm, E.; Ehrsson, H.; Arnér, E.S. Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds. Free Radic. Biol. Med. 2005, 39, 696–703. [Google Scholar] [CrossRef] [PubMed]
  69. Jennette, K.W.; Lippard, S.J.; Vassiliades, G.A.; Bauer, W.R. Metallointercalation reagents. 2-hydroxyethanethiolato(2,2′,2′-terpyridine)-platinum(II) monocation binds strongly to DNA by intercalation. Proc. Natl. Acad. Sci. USA 1974, 71, 3839–3843. [Google Scholar] [CrossRef] [PubMed]
  70. Becker, K.; Herold-Mende, C.; Park, J.J.; Lowe, G.; Schirmer, R.H. Human thioredoxin reductase is efficiently inhibited by (2,2′:6′,2′′-terpyridine)platinum(II) complexes. Possible implications for a novel antitumor strategy. J. Med. Chem. 2001, 44, 2784–2792. [Google Scholar] [CrossRef] [PubMed]
  71. Lo, Y.C.; Ko, T.P.; Su, W.C.; Su, T.L.; Wang, A.H. Terpyridine-platinum(II) complexes are effective inhibitors of mammalian topoisomerases and human thioredoxin reductase 1. J. Inorg. Biochem. 2009, 103, 1082–1092. [Google Scholar] [CrossRef] [PubMed]
  72. Ahmadi, R.; Urig, S.; Hartmann, M.; Helmke, B.M.; Koncarevic, S.; Allenberger, B.; Kienhoefer, C.; Neher, M.; Steiner, H.H.; Unterberg, A.; et al. Antiglioma activity of 2,2′:6′,2′′-terpyridineplatinum(II) complexes in a rat model—Effects on cellular redox metabolism. Free Radic. Biol. Med. 2006, 40, 763–778. [Google Scholar] [CrossRef] [PubMed]
  73. Banti, C.N.; Hadjikakou, S.K. Anti-proliferative and anti-tumor activity of silver(I) compounds. Metallomics 2013, 5, 569–596. [Google Scholar] [CrossRef] [PubMed]
  74. Aaseth, J.; Olsen, A.; Halse, J.; Hovig, T. Argyria-tissue deposition of silver as selenide. Scand. J. Clin. Lab. Investig. 1981, 41, 247–251. [Google Scholar] [CrossRef] [PubMed]
  75. Pellei, M.; Gandin, V.; Marinelli, M.; Marzano, C.; Yousufuddin, M.; Dias, H.V.; Santini, C. Synthesis and biological activity of ester- and amide-functionalized imidazolium salts and related water-soluble coinage metal N-heterocyclic carbene complexes. Inorg. Chem. 2012, 51, 9873–9882. [Google Scholar] [CrossRef] [PubMed]
  76. Citta, A.; Schuh, E.; Mohr, F.; Folda, A.; Massimino, M.L.; Bindoli, A.; Casini, A.; Rigobello, M.P. Fluorescent silver(I) and gold(I)-N-heterocyclic carbene complexes with cytotoxic properties: Mechanistic insights. Metallomics 2013, 5, 1006–1015. [Google Scholar] [CrossRef] [PubMed]
  77. Gandin, V.; Pellei, M.; Marinelli, M.; Marzano, C.; Dolmella, A.; Giorgetti, M.; Santini, C. Synthesis and in vitro antitumor activity of water soluble sulfonate- and ester-functionalized silver(I) N-heterocyclic carbene complexes. J. Inorg. Biochem. 2013, 129, 135–144. [Google Scholar] [CrossRef] [PubMed]
  78. Bergamo, A.; Gaiddon, C.; Schellens, J.H.; Beijnen, J.H.; Sava, G. Approaching tumour therapy beyond platinum drugs: Status of the art and perspectives of ruthenium drug candidates. J. Inorg. Biochem. 2012, 106, 90–99. [Google Scholar] [CrossRef] [PubMed]
  79. Lentz, F.; Drescher, A.; Lindauer, A.; Henke, M.; Hilger, R.A.; Hartinger, C.G.; Scheulen, M.E.; Dittrich, C.; Keppler, B.K.; Jaehde, U. Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation study. Anticancer Drugs 2009, 20, 97–103. [Google Scholar] [CrossRef] [PubMed]
  80. Komeda, S.; Casini, A. Next-generation anticancer metallodrugs. Curr. Top. Med. Chem. 2012, 12, 219–235. [Google Scholar] [CrossRef] [PubMed]
  81. Mura, P.; Camalli, M.; Bindoli, A.; Sorrentino, F.; Casini, A.; Gabbiani, C.; Corsini, M.; Zanello, P.; Rigobello, M.P.; Messori, L. Activity of rat cytosolic thioredoxin reductase is strongly decreased by trans-[bis(2-amino-5- methylthiazole)tetrachlororuthenate(III)]: First report of relevant thioredoxin reductase inhibition for a ruthenium compound. J. Med. Chem. 2007, 50, 5871–5874. [Google Scholar] [CrossRef] [PubMed]
  82. Casini, A.; Gabbiani, C.; Sorrentino, F.; Rigobello, M.P.; Bindoli, A.; Geldbach, T.J.; Marrone, A.; Re, N.; Hartinger, C.G.; Dyson, P.J.; et al. Emerging protein targets for anticancer metallodrugs: Inhibition of thioredoxin reductase and cathepsin B by antitumor ruthenium(II)-arene compounds. J. Med. Chem. 2008, 51, 6773–6781. [Google Scholar] [CrossRef] [PubMed]
  83. Oehninger, L.; Stefanopoulou, M.; Alborzinia, H.; Schur, J.; Ludewig, S.; Namikawa, K.; Munoz-Castro, A.; Koster, R.W.; Baumann, K.; Wolfl, S.; et al. Evaluation of arene ruthenium(II) N-heterocyclic carbene complexes as organometallics interacting with thiol and selenol containing biomolecules. Dalton Trans. 2013, 42, 1657–1666. [Google Scholar] [CrossRef] [PubMed]
  84. Luo, Z.; Yu, L.; Yang, F.; Zhao, Z.; Yu, B.; Lai, H.; Wong, K.H.; Ngai, S.M.; Zheng, W.; Chen, T. Ruthenium polypyridyl complexes as inducer of ROS-mediated apoptosis in cancer cells by targeting thioredoxin reductase. Metallomics 2014, 6, 1480–1490. [Google Scholar] [CrossRef] [PubMed]
  85. Magda, D.; Miller, R.A. Motexafin gadolinium: A novel redox active drug for cancer therapy. Semin. Cancer Biol. 2006, 16, 466–476. [Google Scholar] [CrossRef] [PubMed]
  86. Evens, A.M. Motexafin gadolinium: A redox-active tumor selective agent for the treatment of cancer. Curr. Opin. Oncol. 2004, 16, 576–580. [Google Scholar] [CrossRef] [PubMed]
  87. Hashemy, S.I.; Ungerstedt, J.S.; Zahedi Avval, F.; Holmgren, A. Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase. J. Biol. Chem. 2006, 281, 10691–10697. [Google Scholar] [CrossRef] [PubMed]
  88. Navakoski de Oliveira, K.; Andermark, V.; von Grafenstein, S.; Onambele, L.A.; Dahl, G.; Rubbiani, R.; Wolber, G.; Gabbiani, C.; Messori, L.; Prokop, A.; et al. Butyltin(IV) benzoates: Inhibition of thioredoxin reductase, tumor cell growth inhibition, and interactions with proteins. ChemMedChem 2013, 8, 256–264. [Google Scholar] [CrossRef] [PubMed]
  89. Navakoski de Oliveira, K.; Andermark, V.; Onambele, L.A.; Dahl, G.; Prokop, A.; Ott, I. Organotin complexes containing carboxylate ligands with maleimide and naphthalimide derived partial structures: TrxR inhibition, cytotoxicity and activity in resistant cancer cells. Eur. J. Med. Chem. 2014, 87, 794–800. [Google Scholar] [CrossRef] [PubMed]
  90. Flemming, A. On the specific antibacterial properties of penicillin and potassium tellurite. J. Pathol. Bacteriol. 1932, 35, 831–842. [Google Scholar] [CrossRef]
  91. Engman, L.; Kandra, T.; Gallegos, A.; Williams, R.; Powis, G. Water-soluble organotellurium compounds inhibit thioredoxin reductase and the growth of human cancer cells. Anticancer Drug Des. 2000, 15, 323–330. [Google Scholar] [PubMed]
  92. Engman, L.; Al-Maharik, N.; McNaughton, M.; Birmingham, A.; Powis, G. Thioredoxin reductase and cancer cell growth inhibition by organotellurium antioxidants. Anticancer Drugs 2003, 14, 153–161. [Google Scholar] [CrossRef] [PubMed]
  93. McNaughton, M.; Engman, L.; Birmingham, A.; Powis, G.; Cotgreave, I.A. Cyclodextrin-derived diorganyl tellurides as glutathione peroxidase mimics and inhibitors of thioredoxin reductase and cancer cell growth. J. Med. Chem. 2004, 47, 233–239. [Google Scholar] [CrossRef] [PubMed]
  94. Engman, L.; Al-Maharik, N.; McNaughton, M.; Birmingham, A.; Powis, G. Thioredoxin reductase and cancer cell growth inhibition by organotellurium compounds that could be selectively incorporated into tumor cells. Bioorg. Med. Chem. 2003, 11, 5091–5100. [Google Scholar] [CrossRef] [PubMed]
  95. Lu, J.; Chew, E.H.; Holmgren, A. Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proc. Natl. Acad. Sci. USA 2007, 104, 12288–12293. [Google Scholar] [CrossRef] [PubMed]
  96. Chen, G.Q.; Zhu, J.; Shi, X.G.; Ni, J.H.; Zhong, H.J.; Si, G.Y.; Jin, X.L.; Tang, W.; Li, X.S.; Xong, S.M.; et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RARα/PML proteins. Blood 1996, 88, 1052–1061. [Google Scholar] [PubMed]
  97. Gazitt, Y.; Akay, C. Arsenic trioxide: An anti cancer missile with multiple warheads. Hematology 2005, 10, 205–213. [Google Scholar] [CrossRef] [PubMed]
  98. Hu, J.; Fang, J.; Dong, Y.; Chen, S.J.; Chen, Z. Arsenic in cancer therapy. Anticancer Drugs 2005, 16, 119–127. [Google Scholar] [CrossRef] [PubMed]
  99. Douer, D.; Tallman, M.S. Arsenic trioxide: New clinical experience with an old medication in hematologic malignancies. J. Clin. Oncol. 2005, 23, 2396–2410. [Google Scholar] [CrossRef] [PubMed]
  100. Miller, W.H., Jr.; Schipper, H.M.; Lee, J.S.; Singer, J.; Waxman, S. Mechanisms of action of arsenic trioxide. Cancer Res. 2002, 62, 3893–3903. [Google Scholar] [PubMed]

Share and Cite

MDPI and ACS Style

Gandin, V.; Fernandes, A.P. Metal- and Semimetal-Containing Inhibitors of Thioredoxin Reductase as Anticancer Agents. Molecules 2015, 20, 12732-12756. https://doi.org/10.3390/molecules200712732

AMA Style

Gandin V, Fernandes AP. Metal- and Semimetal-Containing Inhibitors of Thioredoxin Reductase as Anticancer Agents. Molecules. 2015; 20(7):12732-12756. https://doi.org/10.3390/molecules200712732

Chicago/Turabian Style

Gandin, Valentina, and Aristi P. Fernandes. 2015. "Metal- and Semimetal-Containing Inhibitors of Thioredoxin Reductase as Anticancer Agents" Molecules 20, no. 7: 12732-12756. https://doi.org/10.3390/molecules200712732

Article Metrics

Back to TopTop